Brenetafusp is under clinical development by Immunocore and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According to GlobalData, Phase II drugs for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) have an 18% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Brenetafusp’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Brenetafusp overview
Brenetafusp is under development for the treatment of non-small cell lung cancer, synovial sarcoma, small cell lung cancer, ovarian cancer, endometrial cancer, urothelial carcinoma, triple-negative breast cancer , cutaneous melanoma, mucosal melanoma, head and neck squamous cell carcinoma, acute myeloid leukemia and uveal melanoma. It is a bispecific fusion protein comprises of T cell receptor (TCR) with an anti-CD3 single-chain antibody fragment (scFv). The drug candidate is developed based on Immune mobilizing monoclonal T-cell receptor against cancer (ImmTAC) technology. It is administered through intravenous route. The drug candidate acts by targeting preferentially expressed antigen in melanoma (PRAME).
Immunocore overview
Immunocore is a biotechnology company that- focuses on the development of immunotherapeutic drugs for the treatment of cancer, infectious diseases, and autoimmune diseases. The company develops its drugs using proprietary T cell receptor (TCR) technology. Its products under development include IMC-C103C, IMC-F106C, IMC-I109V, IMC-M113V and IMCgp100. The company works in collaboration with various pharmaceutical companies, to develop its product candidates for the treatment of metastatic cutaneous melanoma; cancer; and other indications. It has presence in the UK, the US, Australia, New Zealand and Asia, Europe. Immunocore is headquartered in Oxfordshire, the UK.
For a complete picture of Brenetafusp’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
